… used to treat patients with MM.3,4 These treatment plans significantly … Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020 … , Bringhen S. New drugs in early development for treating multiple myeloma: all that glitters is …

… successful procedures for leukaemia, multiple myeloma, and other benign and … as part of continuous development. The Director noted … by doctors, nurses, pharmacists, and support staff. … detection, screening, and modern treatment, he said, have transformed …

… multiple myeloma patients who had received three or more prior lines of treatment … with proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies. The drug … in a difficult-to-treat patient population. Pharmacy Times: How does …

… providers’ overall treatment goals for patients with multiple myeloma. Transcript What … is the significance of this FDA … a fourth drug in the CEPHEUS trial represents such … of whether we are treating young patients or old …

… —what breakthroughs or clinical developments should pharmacists be watching for in … is shaping equitable and scalable treatment strategies. By convening researchers, … sessions. The pharmacy track BCOP topics include maintenance in Multiple Myeloma, TIL and …

… additional risks, including the development of secondary malignancies, which … data, one clinical trial was discontinued due to … and honoraria from Jazz Pharmaceuticals and MSD, and … diagnosis, treatment and follow-up of patients with multiple myeloma. Nat …

… Key Takeaways for Pharmacist KTX-1001 selectively … relapsed or refractory multiple myeloma patients who had received … proteasome inhibitors, immunomodulatory drugs, and anti-CD38 … differentiating it from broader treatments such as monoclonal antibodies …

… multiple myeloma, according to Surbhi Sidana, MD. In December 2025, the FDA … the phase 3 MajesTEC-3 trial (NCT05083169), which evaluated … developments in the multiple myeloma field may impact the treatment paradigm? With everything in multiple myeloma …

… reporting positive pivotal clinical trial results in December, the … FDA has generally encouraged drugmakers to develop CAR-T meds for … cell lymphoma and multiple myeloma, these one-time treatments may carry … with autoimmune CAR-T drugs to date, no secondary …

… has a broad, treatment-independent influence on multiple myeloma outcomes. Bhasin, professor … translational findings to the development of novel anti-myeloma … complexity of multiple myeloma, which may inform other next-generation treatments. Transcript: …